220 related articles for article (PubMed ID: 30760518)
1. YY1 Complex Promotes Quaking Expression via Super-Enhancer Binding during EMT of Hepatocellular Carcinoma.
Han J; Meng J; Chen S; Wang X; Yin S; Zhang Q; Liu H; Qin R; Li Z; Zhong W; Zhang C; Zhang H; Tang Y; Lin T; Gao W; Zhang X; Yang L; Liu Y; Zhou HG; Sun T; Yang C
Cancer Res; 2019 Apr; 79(7):1451-1464. PubMed ID: 30760518
[TBL] [Abstract][Full Text] [Related]
2. Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation.
Li Y; Kasim V; Yan X; Li L; Meliala ITS; Huang C; Li Z; Lei K; Song G; Zheng X; Wu S
Theranostics; 2019; 9(25):7599-7615. PubMed ID: 31695789
[TBL] [Abstract][Full Text] [Related]
3. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
4. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
5. Molecular interplay between linc01134 and YY1 dictates hepatocellular carcinoma progression.
Rong Z; Wang Z; Wang X; Qin C; Geng W
J Exp Clin Cancer Res; 2020 Apr; 39(1):61. PubMed ID: 32272940
[TBL] [Abstract][Full Text] [Related]
6. Twist1-YY1-p300 complex promotes the malignant progression of HCC through activation of miR-9 by forming phase-separated condensates at super-enhancers and relieved by metformin.
Meng J; Han J; Wang X; Wu T; Zhang H; An H; Qin L; Sun Y; Zhong W; Yang C; Liu H; Sun T
Pharmacol Res; 2023 Feb; 188():106661. PubMed ID: 36669583
[TBL] [Abstract][Full Text] [Related]
7. YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
Dong S; Ma X; Wang Z; Han B; Zou H; Wu Z; Zang Y; Zhuang L
Oncotarget; 2017 Jun; 8(25):40583-40593. PubMed ID: 28489564
[TBL] [Abstract][Full Text] [Related]
8. MiR-142-5p Suppresses Lung Cancer Cell Metastasis by Targeting Yin Yang 1 to Regulate Epithelial-Mesenchymal Transition.
Zhang Q; Liu H; Zhang J; Shan L; Yibureyimu B; Nurlan A; Aerxiding P; Luo Q
Cell Reprogram; 2020 Dec; 22(6):328-336. PubMed ID: 33270501
[TBL] [Abstract][Full Text] [Related]
9. LncRNA LINC00668 promotes cell proliferation, migration, invasion ability and EMT process in hepatocellular carcinoma by targeting miR-532-5p/YY1 axis.
Xuan W; Zhou C; You G
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32249890
[TBL] [Abstract][Full Text] [Related]
10. Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha.
Zhang S; Jiang T; Feng L; Sun J; Lu H; Wang Q; Pan M; Huang D; Wang X; Wang L; Jin H
J Mol Med (Berl); 2012 Sep; 90(9):1069-77. PubMed ID: 22391813
[TBL] [Abstract][Full Text] [Related]
11. Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1.
Song LN; Qiao GL; Yu J; Yang CM; Chen Y; Deng ZF; Song LH; Ma LJ; Yan HL
J Exp Clin Cancer Res; 2020 Jun; 39(1):114. PubMed ID: 32552766
[TBL] [Abstract][Full Text] [Related]
12. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression.
Liu H; Han J; Lv Y; Zhao Z; Zheng S; Sun Y; Sun T
J Nanobiotechnology; 2023 Jul; 21(1):208. PubMed ID: 37408047
[TBL] [Abstract][Full Text] [Related]
13. Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1.
Wang CC; Tsai MF; Dai TH; Hong TM; Chan WK; Chen JJ; Yang PC
Cancer Res; 2007 May; 67(10):4816-26. PubMed ID: 17510411
[TBL] [Abstract][Full Text] [Related]
14. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA LINC01578 drives colon cancer metastasis through a positive feedback loop with the NF-κB/YY1 axis.
Liu J; Zhan Y; Wang J; Wang J; Guo J; Kong D
Mol Oncol; 2020 Dec; 14(12):3211-3233. PubMed ID: 33040438
[TBL] [Abstract][Full Text] [Related]
16. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
17. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.
Zhu K; Dai Z; Pan Q; Wang Z; Yang GH; Yu L; Ding ZB; Shi GM; Ke AW; Yang XR; Tao ZH; Zhao YM; Qin Y; Zeng HY; Tang ZY; Fan J; Zhou J
Clin Cancer Res; 2011 Dec; 17(23):7294-302. PubMed ID: 21976539
[TBL] [Abstract][Full Text] [Related]
18. The RNA-binding protein GRSF1 promotes hepatocarcinogenesis via competitively binding to YY1 mRNA with miR-30e-5p.
Han L; Huang C; Wang X; Tong D
J Exp Clin Cancer Res; 2022 Jan; 41(1):17. PubMed ID: 34998399
[TBL] [Abstract][Full Text] [Related]
19. CircMTO1 suppresses hepatocellular carcinoma progression via the miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling pathway and epithelial-to-mesenchymal transition.
Li D; Zhang J; Yang J; Wang J; Zhang R; Li J; Zhang R
Cell Death Dis; 2021 Dec; 13(1):12. PubMed ID: 34930906
[TBL] [Abstract][Full Text] [Related]
20. QKI, a miR-200 target gene, suppresses epithelial-to-mesenchymal transition and tumor growth.
Kim EJ; Kim JS; Lee S; Lee H; Yoon JS; Hong JH; Chun SH; Sun S; Won HS; Hong SA; Kang K; Jo JY; Choi M; Shin DH; Ahn YH; Ko YH
Int J Cancer; 2019 Sep; 145(6):1585-1595. PubMed ID: 31026342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
